Cover Image
市場調查報告書

PharmaPoint:類風濕性關節炎 - 全球醫藥品的預測與市場分析

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 296460
出版日期 內容資訊 英文 403 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:類風濕性關節炎 - 全球醫藥品的預測與市場分析 PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025
出版日期: 2017年02月01日 內容資訊: 英文 403 Pages
簡介

類風濕性關節炎是慢性自體免疫症的一種,會造成關節部位發炎和變形。全球主要10國的患者總數,目前約有700萬以上,推計到2023年將達到850萬人。抗TNF藥對於治療類風濕性關節炎的症狀·徵兆、抑制發炎性骨骼疾病的惡化上相當有效。但生技仿製藥和新生技藥品,以及被稱為JAK抑制劑的口服治療藥級的出現,一認為市場環境在今後十年將會產生急劇的變化。抗TNF藥本身是非常有效的治療藥,但對新加入企業而言市場卻是競爭極度激烈化,再加上生技仿製藥的認證·上市,競爭壓力更是日益高升。

本報告提供全球類風濕性關節炎治療藥市場相關調查分析,提供您疾病概要,收益實際成果與預測,主要專題 (策略性競爭企業評估,市場特性,未滿足需求,臨床試驗製圖等),再加上開發平台分析,現在/未來市場競爭分析 (推動因素·阻礙因素,課題等) 等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QoL)

第4章 流行病學

  • 疾病的背景
  • 危險因素和併發症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:類風濕性關節炎的患者總數
    • 預測的前提條件與手法:類風濕性關節炎已診斷患者數
  • 類風濕性關節炎的流行病學預測
    • 類風濕性關節炎的患者總數
    • 類風濕性關節炎的各年齡患者數
    • 類風濕性關節炎的男女患者數
    • 類風濕性關節炎已診斷的患者數
    • 類風濕性關節炎已診斷的患者數 (年齡已調整)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療的指南
    • 治療類風濕性關節炎用有代表性的處方藥
    • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌
    • Enbrel (依那西普(Etanercept))
    • Humira (Adalimumab)
    • Remicade (Infliximab)
    • Simponi (golimumab)
    • Cimzia (certolizumab pegol)
    • 6.2.6Orencia (abatacept)
    • actemraRoActemra (tocilizumab)
    • Rituxan/MabThera (Rituximab)
    • Inflectra/Remsima (Infliximab生技仿製藥)
    • Xeljanz (tofacitinib)
    • iguratimod/t-614
    • Methotrexate (許多品牌)
  • 生技仿製藥
    • 簡介
    • 在主要自體免疫疾病方面,Hospira的Inflectra和J & J的Remicade的比較
    • 免疫學機構團體的生技仿製藥
    • 開發中的生技仿製藥的數量
    • 製藥產業整體所感受到的生技仿製藥影響度
    • 類風濕性關節炎用生技仿製藥的普及率預計將依市場而有所不同
    • 生技仿製藥的預測
  • 其他治療方法

第7章 未滿足需求及機會

  • 概要
  • 開發高成本效率的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 預測治療反應度用的生物標記
  • 類風濕性關節炎的早期診斷
  • 個體化治療的方法

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 臨床實驗:各級
  • 臨床實驗階段的有潛力的藥劑
    • Sarilumab
    • Sirukumab
    • Clazakizumab
    • Cosentyx (secukinumab)
    • Tregalizumab
    • Mavrilimumab
    • Denosumab (Prolia/Xgeva)
    • barishichinibu
    • Peficitinib
    • Decernotinib
    • Filgotinib
    • Masitinib
    • raVAX
  • 開發中的其他藥劑

第9章 現在及未來的主要企業

  • 企業策略趨勢
  • 企業簡介
    • AbbVie
    • Pfizer
    • Amgen
    • Johnson & Johnson
    • Eli Lilly
    • Bristol-Myers Squibb
    • UCB
    • Roche
    • GlaxoSmithKline
    • Novartis
    • Sanofi
    • AstraZeneca-MedImmune
    • Astellas Pharma Inc.
    • Vertex
    • 第一三共

第10章 市場預測

  • 全球市場
    • 預測
    • 推動因素及課題:全球問題
  • 美國
    • 預測
    • 主要的活動
    • 推動因素及障礙
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 中國
  • 印度

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease.

The RA market in the 8MM is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the forecast period, from 2015 sales of $19.5 billion to sales of $28.5 billion in 2025.

The major drivers of growth in the global RA market during the forecast period are -

  • An increase in the prevalent cases of RA in all the markets, in part, due to an aging population.
  • The launch and continued uptake of biosimilars for all established biologics on the RA market (infliximab, etanercept, adalimumab, golimumab, certolizumab pegol, tocilizumab, abatacept, and rituximab) in all the markets covered in the report, which is expected to lead to an increase in patient volume by making treatments more accessible.
  • The early diagnosis and treatment of patients with RA to limit disease progression.

The RA market is dominated by Big Pharma, and most of the compounds in late-stage development are backed by a major pharmaceutical company. The major players in the RA market have extensive portfolios, and may enter into Phase I buyouts and partnerships at very early stages. It is especially common for these companies to form an early partnership for development in the Japanese market.

Biosimilars for all established biologics are expected to launch in all 8MM by 2025, with the exception of etanercept in the US and certolizumab in Japan. Overall, the market share of biosimilars will account for 23% of the 8MM RA market in 2025. It is this potential segment of the RA market that Big Pharma companies such as Pfizer and Amgen have realized, and as such are pursuing their own biosimilar development programs.

The report "PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025" provides an overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.

In depth, this report provides the following analysis -

  • Provides comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte's Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune's mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer's Inflectra/Remsima, Samsung Bioepis/Biogen/Merck's Flixabi and Benepali, Sandoz's Erelzi, and Amgen's Amjevita).
  • Provides annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Analysis of strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
  • Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges.

Companies mentioned in this report: AbbVie, Pfizer, Amgen, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, UCB, Roche, GlaxoSmithKline, Novartis, Sanofi, AstraZeneca-MedImmune, Astellas, Daiichi Sankyo, Samsung Bioepis, Sandoz.

Scope

  • Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
  • Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte's Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune's mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer's Inflectra/Remsima, Samsung Bioepis/Biogen/Merck's Flixabi and Benepali, Sandoz's Erelzi, and Amgen's Amjevita).
  • Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the RA market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the eight major RA markets from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 10

  • 1.1 List of Tables 16
  • 1.2 List of Figures 23

2 Introduction 25

  • 2.1 Catalyst 25
  • 2.2 Related Reports 25
  • 2.3 Upcoming Related Reports 26

3 Disease Overview 27

  • 3.1 Etiology and Pathophysiology 27
    • 3.1.1 Etiology 27
    • 3.1.2 Pathophysiology 27
  • 3.2 Symptoms 32
  • 3.3 Prognosis 32
  • 3.4 Quality of Life 33

4 Epidemiology 34

  • 4.1 Disease Background 34
  • 4.2 Risk Factors and Comorbidities 35
  • 4.3 Global Trends 36
    • 4.3.1 Diagnosed Incidence 37
    • 4.3.2 Prevalence 39
  • 4.4 Forecast Methodology 41
    • 4.4.1 Sources Used 41
    • 4.4.2 Forecast Assumptions and Methods 45
    • 4.4.3 Sources Not Used 55
  • 4.5 Epidemiological Forecast for RA (2015-2025) 55
    • 4.5.1 Diagnosed Incident Cases 55
    • 4.5.2 Diagnosed Prevalent Cases 62
    • 4.5.3 Total Prevalent Cases 70
  • 4.6 Discussion 77
    • 4.6.1 Epidemiological Forecast Insight 77
    • 4.6.2 Limitations of the Analysis 78
    • 4.6.3 Strengths of the Analysis 79

5 Disease Management 80

  • 5.1 Diagnosis and Treatment Overview 80
    • 5.1.1 Diagnosis 80
    • 5.1.2 Treatment Guidelines 82
    • 5.1.3 Leading Prescribed Drugs for the Treatment of RA 92
    • 5.1.4 Clinical Practice 93
  • 5.2 US 94
  • 5.3 France 97
  • 5.4 Germany 99
  • 5.5 Italy 102
  • 5.6 Spain 104
  • 5.7 UK 106
  • 5.8 Japan 108
  • 5.9 Australia 110

6 Competitive Assessment 112

  • 6.1 Overview 112
  • 6.2 Product Profiles - Major Brands 113
    • 6.2.1 Enbrel (etanercept) 113
    • 6.2.2 Humira (adalimumab) 119
    • 6.2.3 Remicade (infliximab) 123
    • 6.2.4 Simponi (golimumab) 129
    • 6.2.5 Cimzia (certolizumab pegol) 134
    • 6.2.6 Orencia (abatacept) 139
    • 6.2.7 Actemra/RoActemra (tocilizumab) 145
    • 6.2.8 Rituxan/MabThera (rituximab) 150
    • 6.2.9 Inflectra/Remsima (infliximab biosimilar) 155
    • 6.2.10 Flixabi (infliximab biosimilar) 158
    • 6.2.11 Benepali (etanercept biosimilar) 161
    • 6.2.12 Erelzi (etanercept biosimilar) 164
    • 6.2.13 Amjevita (adalimumab biosimilar) 167
    • 6.2.14 Xeljanz (tofacitinib) 169
    • 6.2.15 Iguratimod/T-614 175
    • 6.2.16 Methotrexate (Numerous Brands) 178
  • 6.3 Biosimilars Assessment 180
    • 6.3.1 Introduction 180
    • 6.3.2 Biosimilars in the Immunology Community 182
    • 6.3.3 By the Numbers: Biosimilars in Development 182
    • 6.3.4 The Impact of Biosimilars Is Being Felt Throughout the Pharmaceutical Industry 187
    • 6.3.5 Uptake of Biosimilars for RA Is Expected to Vary by Market 188
  • 6.4 Other Therapies 192

7 Unmet Needs and Opportunities 193

  • 7.1 Overview 193
  • 7.2 Development of Cost-Effective Therapies 194
    • 7.2.1 Unmet Need 194
    • 7.2.2 Gap Analysis 195
    • 7.2.3 Opportunity 195
  • 7.3 Biomarkers to Predict Responsiveness to Therapy 196
    • 7.3.1 Unmet Need 196
    • 7.3.2 Gap Analysis 197
    • 7.3.3 Opportunity 198
  • 7.4 Early Diagnosis of RA 198
    • 7.4.1 Unmet Need 198
    • 7.4.2 Gap Analysis 199
    • 7.4.3 Opportunity 199
  • 7.5 Personalized Treatment Approach 200
    • 7.5.1 Unmet Need 200
    • 7.5.2 Gap Analysis 200
    • 7.5.3 Opportunity 202

8 Pipeline Assessment 204

  • 8.1 Overview 204
  • 8.2 Clinical Trial Mapping 204
    • 8.2.1 Clinical Trials by Class 204
  • 8.3 Promising Drugs in Clinical Development 205
    • 8.3.1 Sarilumab 209
    • 8.3.2 Sirukumab 218
    • 8.3.3 Clazakizumab 224
    • 8.3.4 Vobarilizumab (ALX-0016) 231
    • 8.3.5 Mavrilimumab 236
    • 8.3.6 Pralia (denosumab) 242
    • 8.3.7 Olumiant (baricitinib) 247
    • 8.3.8 Peficitinib 255
    • 8.3.9 Filgotinib 261
    • 8.3.10 Upadacitinib 269
    • 8.3.11 Piclidenoson 275
  • 8.4 Other Drugs in Development 279

9 Current and Future Players 281

  • 9.1 Trends in Corporate Strategy 284
  • 9.2 Company Profiles 285
    • 9.2.1 AbbVie 285
    • 9.2.2 Pfizer 287
    • 9.2.3 Amgen 289
    • 9.2.4 Johnson & Johnson 292
    • 9.2.5 Eli Lilly 294
    • 9.2.6 Bristol-Myers Squibb 295
    • 9.2.7 UCB 297
    • 9.2.8 Roche 299
    • 9.2.9 GlaxoSmithKline 301
    • 9.2.10 Sanofi 302
    • 9.2.11 AstraZeneca- MedImmune 304
    • 9.2.12 Astellas 306
    • 9.2.13 Daiichi Sankyo 308
    • 9.2.14 Samsung Bioepis 310
    • 9.2.15 Sandoz 312

10 Market Outlook 315

  • 10.1 Global Markets 315
    • 10.1.1 Forecast 315
    • 10.1.2 Drivers and Barriers - Global Issues 319
  • 10.2 US 322
    • 10.2.1 Forecast 322
    • 10.2.2 Key Events 325
    • 10.2.3 Drivers and Barriers 325
  • 10.3 5EU 328
    • 10.3.1 Forecast 328
    • 10.3.2 Key Events 331
    • 10.3.3 Drivers and Barriers 332
  • 10.4 Japan 334
    • 10.4.1 Forecast 334
    • 10.4.2 Key Events 337
    • 10.4.3 Drivers and Barriers 338
  • 10.5 Australia 341
    • 10.5.1 Forecast 341
    • 10.5.2 Key Events 343
    • 10.5.3 Drivers and Barriers 344

11 Appendix 346

  • 11.1 Bibliography 346
  • 11.2 Abbreviations 372
  • 11.3 Methodology 378
  • 11.4 Forecasting Methodology 378
    • 11.4.1 Diagnosed RA Patients 378
    • 11.4.2 Percentage of Drug-Treated Patients 379
    • 11.4.3 Drugs Included in Each Therapeutic Class 379
    • 11.4.4 Launch and Patent Expiry Dates 380
    • 11.4.5 General Pricing Assumptions 381
    • 11.4.6 Individual Drug Assumptions 382
    • 11.4.7 Generic and Biosimilar Erosion 393
    • 11.4.8 Pricing of Pipeline Agents 393
  • 11.5 Primary Research - KOLs Interviewed for This Report 396
  • 11.6 Primary Research - Prescriber Survey 398
  • 11.7 About the Authors 399
    • 11.7.1 Analyst 399
    • 11.7.2 Therapy Area Director 399
    • 11.7.3 Epidemiologist 399
    • 11.7.4 Global Director of Therapy Analysis and Epidemiology 401
  • 11.8 About GlobalData 402
  • 11.9 Disclaimer 402

List of Tables

1.1 List of Tables

  • Table 1: Symptoms of RA 32
  • Table 2: Risk Factors and Comorbidities of RA 35
  • Table 3: 1987 ACR Diagnostic Criteria for RA 37
  • Table 4: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA 42
  • Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA 43
  • Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA 44
  • Table 7: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA 45
  • Table 8: 8MM, Sources Not Used in the Epidemiological Analysis of RA 55
  • Table 9: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 56
  • Table 10: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015 58
  • Table 11: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N (Row %), 2015 60
  • Table 12: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 63
  • Table 13: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015 65
  • Table 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015 67
  • Table 15: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 71
  • Table 16: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015 73
  • Table 17: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015 75
  • Table 18: 1987 ACR Diagnostic Criteria for RA 81
  • Table 19: 2010 ACR/EULAR Diagnostic Criteria for RA 82
  • Table 20: Treatment Guidelines for RA Used by Each Country in the 8MM 84
  • Table 21: ACR 2015 Criteria for RA Remission and Low/Moderate/High Disease Activity 87
  • Table 22: EULAR 2013 Criteria for RA Remission 88
  • Table 23: Most-Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2015 93
  • Table 24: RA Treatment Country Profile - US 96
  • Table 25: RA Treatment Country Profile - France 98
  • Table 26: RA Treatment Country Profile - Germany 101
  • Table 27: RA Treatment Country Profile - Italy 103
  • Table 28: RA Treatment Country Profile - Spain 105
  • Table 29: RA Treatment Country Profile - UK 107
  • Table 30: RA Treatment Country Profile - Japan 109
  • Table 31: RA Treatment Country Profile - Australia 111
  • Table 32: Leading Branded Treatments for RA, 2016 113
  • Table 33: Product Profile - Enbrel 115
  • Table 34: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers 116
  • Table 35: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results 117
  • Table 36: Enbrel SWOT Analysis, 2016 118
  • Table 37: Product Profile - Humira 120
  • Table 38: Humira SWOT Analysis, 2016 122
  • Table 39: Product Profile - Remicade 125
  • Table 40: Remicade SWOT Analysis, 2016 128
  • Table 41: Product Profile - Simponi 131
  • Table 42: Simponi SWOT Analysis, 2016 133
  • Table 43: Product Profile - Cimzia 136
  • Table 44: Cimzia SWOT Analysis, 2016 138
  • Table 45: Product Profile - Orencia 141
  • Table 46: Orencia SWOT Analysis, 2016 144
  • Table 47: Product Profile - Actemra 147
  • Table 48: Actemra SWOT Analysis, 2016 149
  • Table 49: Product Profile - Rituxan 153
  • Table 50: Rituxan SWOT Analysis, 2016 154
  • Table 51: Product Profile - Inflectra/Remsima 156
  • Table 52: Inflectra/Remsima SWOT Analysis, 2016 158
  • Table 53: Product Profile - Flixabi 159
  • Table 54: Flixabi SWOT Analysis, 2016 161
  • Table 55: Product Profile - Benepali 162
  • Table 56: Benepali SWOT Analysis, 2016 164
  • Table 57: Product Profile - Erelzi 165
  • Table 58: Erelzi SWOT Analysis, 2016 166
  • Table 59: Product Profile - Amjevita 168
  • Table 60: Amjevita SWOT Analysis, 2016 169
  • Table 61: Product Profile - Xeljanz 171
  • Table 62: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6 172
  • Table 63: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6 173
  • Table 64: Xeljanz SWOT Analysis, 2016 174
  • Table 65: Product Profile - Iguratimod 176
  • Table 66: Iguratimod SWOT Analysis, 2016 177
  • Table 67: Product Profile - MTX 179
  • Table 68: MTX SWOT Analysis, 2016 180
  • Table 69: Marketed and Pipeline Biosimilars for RA, 2016 183
  • Table 70: Biosimilar Legislations Across the 8MM 189
  • Table 71: Physician Uptake of Biosimilar Products for RA Across the 8MM, 2016 191
  • Table 72: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2016 192
  • Table 73: Unmet Needs and Opportunities in RA, 2016 194
  • Table 74: Comparison of Therapeutic Drug Classes in Development for RA, 2016 209
  • Table 75: Product Profile - Sarilumab 211
  • Table 76: MOBILITY Study Part, A, Results for Sarilumab at Week 12 212
  • Table 77: MOBILITY Study Part B, Results for Sarilumab at Week 52 213
  • Table 78: Safety Results of the Sarilumab Phase III SARIL-RA-ASCERTAIN Trial 214
  • Table 79: Laboratory Results of Sarilumab Phase III SARIL-RA-ASCERTAIN Trial 214
  • Table 80: Sarilumab SWOT Analysis, 2016 217
  • Table 81: Product Profile - Sirukumab 220
  • Table 82: SIRROUND-D Study Results for Sirukumab 221
  • Table 83: Sirukumab SWOT Analysis, 2016 224
  • Table 84: Product Profile - Clazakizumab 226
  • Table 85: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks 227
  • Table 86: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks 227
  • Table 87: Clazakizumab SWOT Analysis, 2016 230
  • Table 88: Product Profile - Vobarilizumab 232
  • Table 89: Phase IIb Study of Vobarilizumab: Efficacy Results for ITT Population at Week 12 233
  • Table 90: Vobarilizumab SWOT Analysis, 2016 235
  • Table 91: Product Profile - Mavrilimumab 237
  • Table 92: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks 238
  • Table 93: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks 239
  • Table 94: Mavrilimumab SWOT Analysis, 2016 242
  • Table 95: Product Profile - Denosumab 243
  • Table 96: Denosumab SWOT Analysis, 2016 247
  • Table 97: Product Profile - Baricitinib 249
  • Table 98: Phase III RA-BEAM Study Results for Baricitinib at Week 12 250
  • Table 99: Phase III RA-BEAM Study Results for Baricitinib at Week 24 251
  • Table 100: Phase III RA-BEACON Study Results for Baricitinib at Week 12 and Week 24 251
  • Table 101: Phase III RA-BUILD Study Results for Baricitnib at Week 12 and Week 24 252
  • Table 102: Baricitinib SWOT Analysis, 2016 255
  • Table 103: Product Profile - Peficitinib 257
  • Table 104: Peficitinib SWOT Analysis, 2016 260
  • Table 105: Product Profile - Filgotinib 262
  • Table 106: DARWIN I Study Results for Filgotinib at Week 12 263
  • Table 107: DARWIN I Study Results for Filgotinib at Week 24 263
  • Table 108: DARWIN II Study Results for Filgotinib at Week 12 264
  • Table 109: DARWIN II Study Results for Filgotinib at Week 24 264
  • Table 110: Filgotinib SWOT Analysis, 2016 268
  • Table 111: Product Profile - Upadacitinib 270
  • Table 112: Upadacitinib Phase IIb BALANCE-I Trial, ACR Responses at Week 12 270
  • Table 113: Upadacitinib Phase IIb BALANCE-II Trial, ACR Responses at Week 12 271
  • Table 114: Upadacitinib SWOT Analysis, 2016 274
  • Table 115: Product Profile - Piclidenoson 275
  • Table 116: Piclidenoson SWOT Analysis, 2016 278
  • Table 117: Drugs in Phase II of Development for RA, 2016 280
  • Table 118: Key Companies in the RA Market, 2016 283
  • Table 119: AbbVie's RA Portfolio Assessment, 2016 286
  • Table 120: AbbVie SWOT Analysis in RA, 2015-2025 287
  • Table 121: Pfizer's RA Portfolio Assessment, 2016 288
  • Table 122: Pfizer SWOT Analysis in RA, 2015-2025 289
  • Table 123: Amgen's RA Portfolio Assessment, 2016 291
  • Table 124: Amgen SWOT Analysis in RA, 2015-2025 291
  • Table 125: J&J's RA Portfolio Assessment, 2016 293
  • Table 126: J&J SWOT Analysis in RA, 2015-2025 294
  • Table 127: Eli Lilly's RA Portfolio Assessment, 2016 295
  • Table 128: Eli Lilly SWOT Analysis in RA, 2015-2025 295
  • Table 129: BMS' RA Portfolio Assessment, 2016 296
  • Table 130: BMS SWOT Analysis in RA, 2015-2025 297
  • Table 131: UCB's RA Portfolio Assessment, 2016 298
  • Table 132: UCB SWOT Analysis in RA, 2015-2025 299
  • Table 133: Roche's RA Portfolio Assessment, 2016 300
  • Table 134: Roche SWOT Analysis in RA, 2015-2025 300
  • Table 135: GSK's RA Portfolio Assessment, 2016 301
  • Table 136: GSK SWOT Analysis in RA, 2015-2025 302
  • Table 137: Sanofi's RA Portfolio Assessment, 2016 303
  • Table 138: Sanofi SWOT Analysis in RA, 2015-2025 304
  • Table 139: AstraZeneca/MedImmune's RA Portfolio Assessment, 2016 306
  • Table 140: AstraZeneca/MedImmune SWOT Analysis in RA, 2015-2025 306
  • Table 141: Astellas' RA Portfolio Assessment, 2016 307
  • Table 142: Astellas SWOT Analysis in RA, 2015-2025 308
  • Table 143: Daiichi Sankyo's RA Portfolio Assessment, 2016 309
  • Table 144: Daiichi Sankyo SWOT Analysis in RA, 2015-2025 310
  • Table 145: Samsung Bioepis' RA Portfolio Assessment, 2016 311
  • Table 146: Samsung Bioepis' SWOT Analysis in RA, 2015-2025 312
  • Table 147: Sandoz's RA Portfolio Assessment, 2016 314
  • Table 148: Sandoz's SWOT Analysis in RA, 2015-2025 314
  • Table 149: Global RA Market - Drivers and Barriers, 2015-2025 319
  • Table 150: Key Events Impacting Sales for RA in the US, 2015-2025 325
  • Table 151: RA Market in the US - Drivers and Barriers, 2015-2025 325
  • Table 152: Key Events Impacting Sales for RA in the 5EU, 2015-2025 331
  • Table 153: RA Market in 5EU - Drivers and Barriers, 2015-2025 332
  • Table 154: Key Events Impacting Sales for RA in Japan, 2015-2025 337
  • Table 155: RA Market in Japan - Drivers and Barriers, 2013-2023 338
  • Table 156: Key Events Impacting Sales for RA in Australia, 2015-2025 343
  • Table 157: RA Market in Australia - Drivers and Barriers, 2013-2023 344
  • Table 158: 8MM, Key Launch Dates of RA Products 380
  • Table 159: 8MM, Key Patent Expiries of RA Products 381
  • Table 160: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 398

List of Figures

1.2 List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA 28
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 31
  • Figure 3: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, 2015-2025 57
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N, 2015 59
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N, 2015 61
  • Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA, Ages ≥18 Years, Cases per 100,000 Population, 2015 62
  • Figure 7: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 64
  • Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N, 2015 66
  • Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N, 2015 68
  • Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of RA, Ages ≥18 Years, %, 2015 69
  • Figure 11: 8MM, Diagnosed Prevalent Cases of RA by Severity, Both Sexes, Ages ≥18 Years, N, 2015 70
  • Figure 12: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 72
  • Figure 13: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2015 74
  • Figure 14: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2015 76
  • Figure 15: 8MM, Age-Standardized Total Prevalence of RA, Ages ≥18 Years, N, 2015 77
  • Figure 16: Disease Management Flowchart for Early RA - ACR 2015 89
  • Figure 17: Disease Management Flowchart for Established RA - ACR 2015 90
  • Figure 18: Flowchart for the Management of RA - EULAR 2013 91
  • Figure 19: Biosimilar Prescribing Habits in RA Across the 8MM, 2016 191
  • Figure 20: RA Clinical Trials by Drug Class, 2016 205
  • Figure 21: RA Phase II-III Pipeline, 2016 206
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2015-2025 208
  • Figure 23: Clinical and Commercial Positioning of Sarilumab 217
  • Figure 24: Clinical and Commercial Positioning of Sirukumab 223
  • Figure 25: Clinical and Commercial Positioning of Clazakizumab 230
  • Figure 26: Clinical and Commercial Positioning of Vobarilizumab 235
  • Figure 27: Clinical and Commercial Positioning of Mavrilimumab 241
  • Figure 28: Clinical and Commercial Positioning of Denosumab in RA 246
  • Figure 29: Clinical and Commercial Positioning of Baricitinib 254
  • Figure 30: Clinical and Commercial Positioning of Peficitinib 260
  • Figure 31: Clinical and Commercial Positioning of Filgotinib 267
  • Figure 32: Clinical and Commercial Positioning of Upadacitinib 273
  • Figure 33: Clinical and Commercial Positioning of Piclidenoson 278
  • Figure 34: Company Portfolio Gap Analysis in RA, 2015-2025 284
  • Figure 35: Global Sales for RA by Region, 2015-2025 318
  • Figure 36: Sales for RA in the US by Drug Class, 2015-2025 324
  • Figure 37: Sales for RA in the 5EU by Drug Class, 2015-2025 330
  • Figure 38: Sales for RA in Japan by Drug Class, 2015-2025 336
  • Figure 39: Sales for RA in Australia by Drug Class, 2015-2025 342
Back to Top